Grant of awards and options

GlaxoSmithKline PLC
16 December 2003

Issued - 16 December 2003, London

                     Grant of awards and options under the

GlaxoSmithKline Performance Share Plan and the GlaxoSmithKline Share Option Plan

On 15 December 2003 the Company granted awards and options under the terms of
the GlaxoSmithKline Performance Share Plan and the GlaxoSmithKline Share Option
Plan (which were both approved by shareholders on 31 July 2000) to senior
executives in the group, including the executive directors.

Performance Share Plan

Under the terms of the Performance Share Plan, target awards designate a number
of ordinary shares or American Depositary Shares (ADSs) that may be awarded,
with the percentage of awards vesting subject to a performance condition which
applies over a three year measurement period which will commence on 1 January
2004 and end on 31 December 2006.

The performance condition compares the Total Shareholder Return (TSR) of the
Company's shares with the TSR of the shares of 14 comparator companies over the
three year period. No target awards will vest if the Company delivers returns
below 8th position in the comparator group, with a sliding scale applying up to
100% vesting for first or second position in the comparator group.

The companies in the comparator group are Abbott Laboratories, AstraZeneca,
Aventis, Bristol Myers Squibb, Eli Lilly & Co., Johnson & Johnson, Merck,
Novartis, Pfizer, Roche, Sanofi-Synthelabo, Schering-Plough, Takeda Chemical
Industries and Wyeth.

Details of the target awards granted to the executive directors on 15 December
2003 are as follows:
                         Number of target awards in respect of ordinary shares or ADSs potentially vesting
TSR position                       Dr J - P Garnier                              Mr J D Coombe

                                        (ADSs)                                      (Shares)
1st or 2nd                              200,000                                     120,000
3rd                                     180,000                                     108,000
4th                                     160,000                                      96,000
5th                                     140,000                                      84,000
6th                                     120,000                                      72,000
7th                                     100,000                                      60,000
8th (median)                            70,000                                       42,000
9th and below                             Nil                                         Nil

One ADS represents two ordinary shares. Where the Company's position falls
between 3rd and 8th position, the level of vesting between the minimum and
maximum figures set out above will be calculated based on the Company's TSR
relative to the TSR of the comparator companies immediately above and below it.

Share Option Plan

Under the terms of the Share Option Plan, options allow the holder to buy shares
or ADSs at a future date at a price determined by reference to the market price
of shares at the time of grant. Options were granted on 15 December 2003 with a
subscription price of £12.70 (or US$44.57 in the case of ADSs).

The Initial Performance Period will be the three financial years of the
Company starting on 1 January 2004. To the extent that the Option does not vest
at the end of the Initial Performance Period, performance will be re-measured
over an Extended Performance Period starting on 1 January 2004 and ending on 31
December 2007. If and to the extent that an Option does not vest at the end of
the Extended Performance Period, it will immediately lapse and cease to be
exercisable.

The performance condition compares the compound annual increase in the Company's
earnings per share (EPS) with the compound annual increase in the Retail Prices
Index (RPI) over the performance period. No options vest unless the Company's
EPS increase exceeds RPI by 3%, with 50% vesting for an increase of 3% in excess
of RPI and a sliding scale applying up to 100% vesting for an increase of 5% or
more in excess of RPI.

Details of the target awards granted to the executive directors on 15 December
2003 are as follows:
                                 Number of options over ordinary shares or ADSs potentially vesting
EPS growth                           Dr J - P Garnier                            Mr J D Coombe

                                          (ADSs)                                   (Shares)
RPI+5% or more                            460,000                                   276,000
RPI+ (4%-4.99%)                           345,000                                   207,000
RPI+ (3%-3.99%)                           230,000                                   138,000
Less than RPI+3%                            Nil                                       Nil

One ADS represents two ordinary shares.

S M Bicknell
Company Secretary
16th December 2003











Enquiries:

UK Media enquiries:                                    Martin Sutton            [phone]
                                                       David Mawdsley           [phone]
                                                       Chris Hunter-Ward        [phone]

US Media enquiries:                                    Nancy Pekarek            [phone]
                                                       Mary Anne Rhyne          [phone]
                                                       Patricia Seif            [phone]

European Analyst/Investor enquiries:                   Duncan Learmouth         [phone]
                                                       Anita Kidgell            [phone]
                                                       Philip Thomson           [phone]

US Analyst/ Investor enquiries:                        Frank Murdolo            [phone]
                                                       Tom Curry                [phone]




                      This information is provided by RNS
            The company news service from the London Stock Exchange